Subtype
Clear Cell Renal Cell Carcinoma
CI-CAN-00004976CCRCCExplore in graph →
115 active trials2 approved drugs19 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004976CCRCCExplore in graph →
Clinical trials
248 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (39)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07223541 | Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma(LAG-BOOST) | recruiting | Phase 2 | 72 | University of OklahomaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07389629 | Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | recruiting | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07386158 | Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC | recruiting | Phase 2 | 21 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT04989959 | [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma | recruiting | Phase 1 | 35 | Orhan Kemal OzOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT04510597 | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial(PROBE) | recruiting | Phase 3 | 364 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07097935 | Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 104 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06750419 | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | recruiting | Phase 3 | 82 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06690697 | Combination of Toripalimab and JS004 Therapy for ccRCC | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06519760 | 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06613269 | 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.(NYCRRT) | recruiting | Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06399419 | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | recruiting | Phase 1 | 28 | Osel, Inc.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT06211790 | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT05214885 | Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma | recruiting | — | 300 | Qianfoshan HospitalOTHER | 1 | Mar 9, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 2, 2026source: clinicaltrials